NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/26/2026 14:32
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization96.63 mln
Float32.20 mln
Earnings Date09/10/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
79
/ 100
Strongly outperforming
Debt / Equity
0.01
Debt-free
ROE
-63.82
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Anixa Biosciences is a California-based medical research company working to develop new treatments and preventive vaccines for some of the most difficult-to-treat cancers, including ovarian, breast, lung, colon, and prostate cancer. The company is advancing a specialized immune cell therapy designed to fight ovarian cancer, alongside a breast cancer vaccine and a broader program aimed at discovering vaccines for other hard-to-treat cancers. Founded in 1982 and headquartered in San Jose, Anixa operates at the cutting edge of cancer science, exploring how certain proteins in the body could serve as targets for next-generation cancer vaccines.
